Document 0522
 DOCN  M9480522
 TI    Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind
       trial.
 DT    9410
 AU    White AC Jr; Chappell CL; Hayat CS; Kimball KT; Flanigan TP; Goodgame
       RW; Dept. of Medicine, Baylor College of Medicine, Houston, TX 77030.
 SO    J Infect Dis. 1994 Aug;170(2):419-24. Unique Identifier : AIDSLINE
       MED/94308611
 AB    To test the effects of paromomycin, 10 patients with AIDS and
       cryptosporidiosis were randomized to paromomycin or placebo in a
       double-blind trial. After 14 days, patients were switched to the other
       treatment for 14 additional days. Measures included the number and
       character of each stool and weekly 24-h stool specimens for weight and
       oocyst excretion. During the paromomycin treatment phase, oocyst
       excretion decreased from 314 x 10(6) to 109 x 10(6)24 h (P < .02).
       Oocyst excretion increased for the 4 patients initially on placebo
       compared to a median decrease of 128 x 10(6)/24 h for the 6 initially
       treated with drug (P < .02). Stool frequency also decreased more in
       those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends
       favored drug over placebo for stool weight, stool character, and
       Karnofsky score. Paromomycin treatment resulted in improvement in both
       clinical and parasitologic parameters in cryptosporidiosis in AIDS.
 DE    Adult  AIDS-Related Opportunistic Infections/*DRUG THERAPY
       Cryptosporidiosis/*DRUG THERAPY  Diarrhea/DRUG THERAPY  Double-Blind
       Method  Feces/PARASITOLOGY  Human  Longitudinal Studies  Parasite Egg
       Count  Paromomycin/*THERAPEUTIC USE  Prospective Studies  Support,
       Non-U.S. Gov't  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED CONTROLLED
       TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).